IL13 and systemic sclerosis: For example, fresolimumab, a pan‐specific TGF‐β (including TGF‐β1, 2, 3)‐neutralizing antibody, reversed markers of skin fibrosis and improved clinical symptoms in systemic sclerosis patients.[18] However, indicated by the failure of recent clinical trials targeting single cytokines or their receptors like IL‐13,[7a,b] IL‐1,[7c] IL‐6R,[7d] specific antibody intervention alone had only a modest effect on reversing fibrosis, highlighting that fibrotic disorders are orchestrated by a variety of cytokines.